Adenovirus-derived vectors for prostate cancer gene therapy

Vrij, J. de; Willemsen, R.A.; Lindholm, L.; Hoeben, R.C.; Bangma, C.H.; Barber, C.; ... ; GIANT Consortium (2010)

Article / Letter to editor

Prostate cancer is a leading cause of death among men in Western countries. Whereas the survival rate approaches 100% for patients with localized cancer, the results of treatment in patients with metastasized prostate cancer at diagnosis are much less successful. The patients are usually presented with a variety of treatment options, but therapeutic interventions in prostate cancer are associated with frequent adverse side effects. Gene therapy and oncolytic virus therapy may constitute new strategies. Already a wide variety of preclinical studies has demonstrated the therapeutic potential of such approaches, with oncolytic prostate-specific adenoviruses as the most prominent vector. The state of the art and future prospects of gene therapy in prostate cancer are reviewed, with a focus on adenoviral vectors. We summarize advances in adenovirus technology for prostate cancer treatment and highlight areas where further developments are necessary.

• All authors: Vrij, J. de; Willemsen, R.A.; Lindholm, L.; Hoeben, R.C.; Bangma, C.H.; Barber, C.; Behr, J.P.; Briggs, S.; Carlisle, R.; Cheng, W.S.; Dautzenberg, I.J.; Ridder, C. de; Dzojic, H.; Erbacher, P.; Essand, M.; Fisher, K.; Frazier, A.; Georgopoulos, L.J.; Jennings, I.; Kochanek, S.; Koppers-Lalic, D.; Kraaij, R.; Kreppel, F.; Magnusson, M.; Maitland, N.; Neuberg, P.; Nugent, R.; Ogris, M.; Remy, J.S.; Scaife, M.; Schenk-Braat, E.; Schooten, E.; Seymour, L.; Slade, M.; Szyjanowicz, P.; Totterman, T.; Uil, T.G.; Ulbrich, K.; Weel, L. van der; Weerden, W. van; Wagner, E.; Zuber, G.; GIANT Consortium
• Date: 2010-07-31
• Volume: 21
• Issue: 7
• Pages: 795 - 805
• DOI: doi:10.1089/hum.2009.203